Nanosized sustained-release pyridostigmine bromide microcapsules: Process optimization and evaluation of characteristics

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 737-745

  Tan, Qunyou ^a   Jiang, Rong ^b   Xu, Meiling ^b,c   Liu, Guodong ^a   Li, Songlin ^a   Zhang, Jingqing ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c CHONGQING EMERGENCY MEDICAL CENTER   (China)

Author keywords

Characteristics; Nanosized microcapsules; Process optimization; Pyridostigmine bromide; Sustained release

Indexed keywords

POLYLACTIC ACID; POLYVINYL ALCOHOL; PYRIDOSTIGMINE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; HUMAN; IN VITRO STUDY; MATERIAL STATE; MICROCAPSULE; PARTICLE SIZE; PH; PROCESS OPTIMIZATION; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

CHARACTERISTICS; NANOSIZED MICROCAPSULES; PROCESS OPTIMIZATION; PYRIDOSTIGMINE BROMIDE; SUSTAINED-RELEASE;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; NANOCAPSULES; PARTICLE SIZE; POLYMERS; PYRIDOSTIGMINE BROMIDE; REPRODUCIBILITY OF RESULTS;

EID: 84874386610     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40860     Document Type: Article

References (31)

1. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol. 2010;17:1445-1450.
2. Maselli RA, Henderson JD, Ng J, Follette D, Graves G, Wilson BW. Protection of human muscle acetylcholinesterase from soman by pyridostigmine bromide. Muscle Nerve. 2011;43:591-595.
3. Tan Q, Hu N, Liu G, et al. Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. Arch Pharm Res. 2012;35:499-508.
4. Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985;37:495-501.
5. White MC, De Silva P, Havard CW. Plasma pyridostigmine levels in myasthenia gravis. Neurology. 1981;31:145-150.
6. Sieb JP, Köhler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clin Neurol Neurosurg. 2010;112:781-784.
7. Hegazy N, Demirel M, Yazan Y. Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int J Pharm. 2002;242: 171-174.
8. Huang YT, Tsai TR, Cheng CJ, Cham TM, Lai TF, Chuo WH. Formulation design of an HPMC-based sustained release tablet for pyridostigmine bromide as a highly hygroscopic model drug and its in vivo/in vitro dissolution properties. Drug Dev Ind Pharm. 2007;33:1183-1191.
9. Adair JH, Parette MP, Altinoglu EI, Kester M. Nanoparticulate alternatives for drug delivery ACS Nano. 2010;4:4967-4970.
10. Fu J, Wang D, Wang T, et al. High entrapment efficiency of chitosan/polylactic acid/tripolyphotspate nanosized microcapsules for rapamycin by an emulsion-evaporation approach. J Biomed Nanotechnol. 2010;6: 725-728.
11. Tan QY, Wang N, Yang H, et al. Preparation and characterization of lipid vesicles containing uricase. Drug Deliv. 2010;17:28-37.
12. Silva AT, Nguyen A, Ye C, Verchot J, Moon JH. Conjugated polymer nanoparticles for effective siRNA delivery to tobacco BY-2 protoplasts. BMC Plant Biol. 2010;10:291.
13. Freitas MN, Marchetti JM. Nimesulide PLA microspheres as a potential sustained release system for the treatment of inflammatory diseases. Int J Pharm. 2005;295:201-211.
14. Chaisria W, Hennink WE, Okonogi S. Preparation and characterization of cephalexin loaded PLGA microspheres. Curr Drug Deliv. 2009;6: 69-75.
15. Cui F, Cun D, Tao A, et al. Preparation and characterization of melittin-loaded poly(DL-lactic acid) or poly (DL-lactic-co-glycolic acid) microspheres made by the double emulsion method. J Control Release. 2005;107:310-319.
16. Musumeci T, Ventura CA, Giannone L, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325:172-179.
17. Zhang JQ, Liu J, Li XL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv. 2007;14: 381-387.
18. Rodenas V, Parra A, Garcia-Villanova J, Gomez MD. Simultaneous determination of cefepime and L-arginine in injections by second-derivative spectrophotometry. J Pharm Biomed Anal. 1995;13:1095-1099.
19. El-Gindy A, Emara S, Hadad GM. Determination of certain drugs in binary mixtures formulations by second derivative ratio spectrophotometry and LC. Farmaco. 2004;59:703-712.
20. Zhang JQ, Zhang ZR, Yang H, Tan QY, Qing SR, Qiu XL. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res. 2005;22:573-583.
21. Liu J, Qiu Z, Wang S, Zhou L, Zhang S. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. Biomed Mater. 2010;5:065002.
22. Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J Biomed Nanotechnol. 2010;6:648-657.
23. Kumari A, Yadav SK, Pakade YB, et al. Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles. Colloids Surf B Biointerfaces. 2011;82:224-232.
24. Lan CH, Rémi F, Yves W. Increase in stability and change in supramolecular structure of b-carotene through encapsulation into polylactic acid nanoparticles. Food Chem. 2011;124:42-49.
25. Kunii R, Onishi H, Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm. 2007;67:9-17.
26. Hou ZQ, Zhou CX, Luo Y, et al. PLA nanoparticles loaded with an active lactone form of hydroxycamptothecin: development, optimization, and in vitro-in vivo evaluation in mice bearing h22solid tumor. Drug Dev Res. 2011;72:1-9.
27. Leo E, Brina B, Forni F, Vandelli MA. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm. 2004;278:133-141.
28. Tan QY, Wang N, Yang H, et al. Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm. 2010;384: 165-172.
29. Tan Q, Li Y, Wu J, Mei H, Zhao C, Zhang J. An optimized molecular inclusion complex of diferuloylmethane: enhanced physical properties and biological activity. Int J Nanomedicine. 2012;7:5285-5393.
30. Magenheim B, Levy MY, Benita S. A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm. 1993;94:115-123.
31. He D, Deng P, Yang L, et al. Molecular encapsulation of rifampicin as an inclusion complex of hydroxypropyl-β-cyclodextrin: Design; characterization and in vitro dissolution. Colloids Surf B Biointerfaces. 2012;103C:580-585.